var data={"title":"Tetrastarch (Hydroxyethyl starch 130/0.4; Voluven): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Tetrastarch (Hydroxyethyl starch 130/0.4; Voluven): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/414090?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=tetrastarch-hydroxyethyl-starch-130-0-4-voluven-drug-information\" class=\"drug drug_general\">see &quot;Tetrastarch (Hydroxyethyl starch 130/0.4; Voluven): Drug information&quot;</a> and <a href=\"topic.htm?path=tetrastarch-hydroxyethyl-starch-130-0-4-voluven-patient-drug-information\" class=\"drug drug_patient\">see &quot;Tetrastarch (Hydroxyethyl starch 130/0.4; Voluven): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10074407\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Voluven</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10074408\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Volulyte;</li>\n      <li>Voluven</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10485746\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Plasma Volume Expander, Colloid</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15578078\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> With severe dehydration, administer crystalloid first. Dose and rate of infusion dependent on amount of blood lost, on maintenance or restoration of hemodynamics, and on amount of hemodilution. Titrate to individual colloid needs, hemodynamics, and hydration status. Do not use in critically ill patients, those undergoing open heart surgery with cardiopulmonary bypass, or those with preexisting renal dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Volume expansion:</b> IV infusion: Usual range: 7-25 mL/kg/dose; maximum daily dose: 50 mL/kg/<b>day</b>; in clinical trials of intraoperative use, a dose of 10 mL/kg/dose has been reported (Osthaus, 2008; Witt, 2008)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10485754\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=tetrastarch-hydroxyethyl-starch-130-0-4-voluven-drug-information\" class=\"drug drug_general\">see &quot;Tetrastarch (Hydroxyethyl starch 130/0.4; Voluven): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> With severe dehydration, administer crystalloid first. Dose and rate of infusion dependent on amount of blood lost, on maintenance or restoration of hemodynamics, and on amount of hemodilution. Titrate to individual colloid needs, hemodynamics, and hydration status. Do not use in critically ill patients, those undergoing open heart surgery with cardiopulmonary bypass, or those with preexisting renal dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants, Children, and Adolescents: <b>Volume expansion:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children &lt;2 years: IV infusion: Usual range: 7-25 mL/kg/dose; mean reported dose: 16 &plusmn; 9 mL/kg/dose; maximum daily dose: 50 mL/kg/<b>day</b>; in clinical trials of intraoperative use, a dose of 10 mL/kg/dose has been reported (Chong Sung, 2006; Osthaus, 2008; Witt, 2008). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2-12 years: IV infusion: Usual range: 25-47 mL/kg/dose; mean reported dose: 36 &plusmn; 11 mL/kg/dose; maximum daily dose: 50 mL/kg/<b>day</b>; in clinical trials of intraoperative use, a dose of 10 mL/kg/dose has been reported (Chong Sung, 2006; Osthaus, 2008; Witt, 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents &gt;12 years: IV Infusion: Administer up to 50 mL/kg/<b>day</b> (or up to 3500 mL daily in a 70 kg patient); may administer repetitively over several days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults: <b>Volume expansion:</b> IV infusion: Administer up to 50 mL/kg/<b>day</b> (or up to 3500 mL daily in a 70 kg patient); may administer repetitively over several days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Avoid use in patients with pre-existing renal dysfunction; discontinue use at the first sign of renal injury.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> No dosage adjustments provided in manufacturer&rsquo;s labeling; use with caution in severe impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10074457\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Voluven: 6% (500 mL) [dehp free, latex free, pvc free]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10074410\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10927865\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer IV only; may be administered via infusion pump or pressure infusion; if administered by pressure infusion, air should be withdrawn or expelled from bag prior to infusion to prevent air embolus. Infuse the first 10-20 mL slowly to observe for anaphylaxis; have epinephrine and resuscitative equipment available. Change IV tubing at least once every 24 hours. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10074431\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F); do not freeze.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10485747\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment and prophylaxis of hypovolemia (FDA approved in all ages); <b>Note:</b> This is not a substitute for blood or plasma; does not have oxygen-carrying capacity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50876134\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Voluven may be confused with VoLumen</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10074425\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus (dose dependent; may be delayed), skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Increased serum amylase</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, coagulation time increased, decreased clotting factors, decreased hematocrit, prolonged prothrombin time, wound hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Acute renal failure, anaphylactoid reaction, anaphylaxis, bradycardia, bronchospasm, circulatory shock, flu-like symptoms, hypersensitivity reaction, hypotension, non-cardiogenic pulmonary edema, shock, tachycardia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10074418\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to hydroxyethyl starch or any component of the formulation; renal failure with oliguria or anuria (not related to hypovolemia); dialysis; any fluid overload condition (eg, pulmonary edema, congestive heart failure); severe hypernatremia; severe hyperchloremia; patients with intracranial bleeding; critically ill adult patients, including patients with sepsis, due to increased risk of mortality and renal replacement therapy; severe liver disease; preexisting coagulation or bleeding disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Volulyte only: Severe hyperkalemia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10074419\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid reactions: Anaphylactoid reactions (eg, mild influenza-like symptoms, bradycardia, tachycardia, bronchospasm, noncardiac pulmonary edema) have been reported with solutions containing hydroxyethyl starch; discontinue use immediately with signs of hypersensitivity and administer appropriate therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding: Monitor the coagulation status in patients undergoing open heart surgery in association with cardiopulmonary bypass. HES solutions have been associated with excess bleeding in these patients. Discontinue use of HES at the first sign of coagulopathy. Use is contraindicated in patients with preexisting coagulation or bleeding disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fluid overload: Administration may cause fluid overload; use with caution in patients at risk from overexpansion of blood volume (eg, very young patients, elderly patients); use is contraindicated in heart failure or any preexisting condition where volume overload is a potential concern. Adjust the dosage in patients with preexisting cardiac dysfunction. Avoid use in patients with preexisting renal dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemodilution: Large volumes may cause a reduction in hematocrit, coagulation factors and other plasma proteins due to hemodilution; coagulation may be impaired (eg, prolonged PT, PTT, and clotting times) and a transient prolongation of bleeding time may be observed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Monitor liver function at baseline and periodically during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment. Monitor liver function at baseline and periodically during treatment. Use is contraindicated in patients with severe liver disease; may result in further reduction of coagulation factors, increasing the risk of bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Avoid use in patients with preexisting renal impairment; fluid status including urine output should be monitored closely; discontinue use at the first sign of renal injury. Use is contraindicated with oliguria or anuria unrelated to hypovolemia or patients receiving hemodialysis.</p>\n    <p style=\"text-indent:0em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Critically-ill patients: <b>[US Boxed Warning]: HES solutions have been associated with mortality and renal injury requiring renal replacement therapy in critically-ill patients, including patients with sepsis; avoid use in critically-ill adult patients, including those with sepsis.</b> Use should also be avoided in patients admitted to the ICU (Brunkhorst, 2008; Perel, 2011; Perner, 2012; Zarychanski, 2009). The Society of Critical Care Medicine (SCCM) also recommends against the use of HES solutions for fluid resuscitation of severe sepsis and septic shock; crystalloids (eg, sodium chloride, Ringer&rsquo;s lactate) are recommended as the fluid of choice for initial resuscitation and subsequent intravascular volume replacement (Rhodes 2017). If used in patients who are not critically ill, avoid use in patients with preexisting renal dysfunction and discontinue use at the first sign of renal injury. Since the need for renal replacement therapy has been reported up to 90 days after HES administration, continue to monitor renal function in all patients for at least 90 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Not a substitute for red blood cells or coagulation factors. Severely dehydrated patients should be infused with a sufficient volume of crystalloid solution initially, prior to consideration of tetrastarch administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Laboratory test interference: May cause temporarily elevated serum amylase levels and interfere with pancreatitis diagnosis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25955839\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">HES use has also been associated with acute kidney injury in pediatric patients (Reinhart, 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300129\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10140508\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=16069&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Arbekacin: Tetrastarch may enhance the nephrotoxic effect of Arbekacin. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10074416\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14079782\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10485756\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure, heart rate, capillary refill time, CVP, RAP, MAP; if pulmonary artery catheter in place, monitor cardiac index, PCWP, SVR, and PVR; hemoglobin, coagulation parameters, renal function (continue to monitor for at least 90 days after administration), urine output, acid-base balance</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10074432\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Produces plasma volume expansion by virtue of its highly colloidal starch structure </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10074434\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: &ge;6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 5.9 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Molecules &gt;50,000 daltons are metabolized by plasma &alpha;-amylase</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (smaller hydroxyethyl starch molecules [&lt;50,000 daltons] unchanged, metabolites)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clearance: 31.4 mL/minute </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10485758\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Voluven&reg;: 6% hetastarch (130/0.4) in 0.9% sodium chloride </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Molecular weight: ~130,000 </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Sodium: 154 mEq/L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Chloride: 154 mEq/L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Osmolarity: 308 mOsm/L</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322845\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Voluven Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6-0.9% (500 mL): $61.06</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10962021\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Tetrahes (ID, KR);</li>\n      <li>TetraHES (TZ);</li>\n      <li>Tetraspan (DK, EE, HK, NO, PH, TW);</li>\n      <li>Volulyte (CZ, DK);</li>\n      <li>Voluven (AE, AR, AT, AU, BH, CH, CL, CN, CR, CU, CY, DO, EE, ES, FI, FR, GR, GT, HK, HN, HR, ID, IL, IS, JP, KR, LT, LU, LV, MY, NI, NL, NO, NZ, PA, PH, PL, PT, QA, RO, SA, SE, SG, SI, SK, SV, TH, TW, UY)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Brunkhorst FM, Engel C, Bloos F, et al, &ldquo;Intensive Insulin Therapy and Pentastarch Resuscitation in Severe Sepsis,&rdquo; <i>N Engl J Med</i>, 2008, 358(2):125-39.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-pediatric-drug-information/abstract-text/18184958/pubmed\" target=\"_blank\" id=\"18184958\">18184958</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chong Sung K, Kum Suk P, Mi Ja Y, et al, &quot;Effects of Intravascular Volume Therapy Using Hydroxyethyl Starch (130/0.4) on Post-Operative Bleeding and Transfusion Requirements in Children Undergoing Cardiac Surgery: A Randomized Clinical Trial,&quot; <i>Acta Anaesthesiol Scand</i>, 2006, 50(1):108-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-pediatric-drug-information/abstract-text/16451158/pubmed\" target=\"_blank\" id=\"16451158\">16451158</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dellinger RP, Levy MM, Rhodes A, et al, &quot;Surviving Sepsis Campaign: International Guidelines For Management of Severe Sepsis and Septic Shock: 2012,&quot; <i>Crit Care Med</i>, 2013, 41(2):580-637.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-pediatric-drug-information/abstract-text/23353941/pubmed\" target=\"_blank\" id=\"23353941\">23353941</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hanart C, Khalife M, De Vill&eacute; A, et al, &quot;Perioperative Volume Replacement in Children Undergoing Cardiac Surgery: Albumin Versus Hydroxyethyl Starch 130/0.4,&quot; <i>Crit Care Med</i>, 2009, 37(2):696-701.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-pediatric-drug-information/abstract-text/19114887/pubmed\" target=\"_blank\" id=\"19114887\">19114887</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lochbuhler H, Galli C, and Hagemann H, &quot;Hydroxylethyl Starch HES 130/0.4 in Paediatric Surgery: Results on an Explorative, Controlled, Multicenter Safety Study,&quot; <i>Crit Care</i>, 2003, 7(2 Suppl): 107.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Osthaus WA, Witt L, Johanning K, et al, &quot;Equal Effects of Gelatin and Hydroxyethyl Starch (6% HES 130/0.42) on Modified Thrombelastography in Children,&quot; <i>Acta Anaesthesiol Scand</i>, 2009, 53(3):305-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-pediatric-drug-information/abstract-text/19173690/pubmed\" target=\"_blank\" id=\"19173690\">19173690</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perel P and Roberts I, &ldquo;Colloids versus Crystalloids for Fluid Resuscitation in Critically Ill Patients,&rdquo; <i>Cochrane Database Syst Rev</i>, 2012, 6:CD000567.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-pediatric-drug-information/abstract-text/22696320/pubmed\" target=\"_blank\" id=\"22696320\">22696320</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perner A, Haase N, Guttormsen AB, et al, &ldquo;Hydroxyethyl Starch 130/0.4 versus Ringer&rsquo;s Acetate in Severe Sepsis,&rdquo; <i>N Engl J Med</i>, 2012, 367(2):124-34; published erratum appears in <i>N Engl J Med</i>, 2012, 367(5):481.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-pediatric-drug-information/abstract-text/22738085/pubmed\" target=\"_blank\" id=\"22738085\">22738085</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reinhart K, Perner A, Sprung CL, et al, &ldquo;Consensus Statement of the ESICM Task Force on Colloid Volume Therapy in Critically Ill Patients,&rdquo; <i>Intensive Care Med</i>, 2012, 38(3):368-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-pediatric-drug-information/abstract-text/22323076/pubmed\" target=\"_blank\" id=\"22323076\">22323076</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    S&uuml;mpelmann R, Kretz FJ, G&auml;bler R, et al, &quot;Hydroxyethyl Starch 130/0.42/6:1 for Perioperative Plasma Volume Replacement in Children: Preliminary Results of a European Prospective Multicenter Observational Postauthorization Safety Study (PASS),&quot; <i>Paediatr Anaesth</i>, 2008, 18(10):929-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-pediatric-drug-information/abstract-text/18647272/pubmed\" target=\"_blank\" id=\"18647272\">18647272</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Witt L, Osthaus WA, J&uuml;ttner B, et al, &quot;Alteration of Anion Gap and Strong Ion Difference Caused by Hydroxyethyl Starch 6% (130/0.42) and Gelatin 4% in Children,&quot; <i>Paediatr Anaesth</i>, 2008, 18(10):934-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-pediatric-drug-information/abstract-text/18811828/pubmed\" target=\"_blank\" id=\"18811828\">18811828</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zarychanski R, Turgeon AF, Fergusson DA, et al, &ldquo;Renal Outcomes and Mortality Following Hydroxyethyl Starch Resuscitation of Critically Ill Patients: Systematic Review and Meta-Analysis of Randomized Trials&rdquo; <b>ATTENTION:</b> The analysis and conclusions of this article are being revised by the authors. This is due to the journal Anesthesia and Analgesia's retraction of a paper by Dr. Joachim Boldt, an author in seven of the studies analyzed in this review. As such, the editors of Open Medicine recommend interpreting this review with extreme caution until Zarychanski et al. publish a new analysis and interpretation in Open Medicine. For more information, see Anesthesia and Analgesia's press release. Open Med, 2009, 3(4):e196-209.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tetrastarch-hydroxyethyl-starch-130-0-4-voluven-pediatric-drug-information/abstract-text/21688756/pubmed\" target=\"_blank\" id=\"21688756\">21688756</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16069 Version 69.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F10074407\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F10074408\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F10485746\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F15578078\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F10485754\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F10074457\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F10074410\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10927865\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F10074431\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10485747\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F50876134\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F10074425\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F10074418\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F10074419\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25955839\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300129\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F10140508\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F10074416\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F14079782\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F10485756\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F10074432\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F10074434\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F10485758\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322845\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10962021\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/16069|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=tetrastarch-hydroxyethyl-starch-130-0-4-voluven-drug-information\" class=\"drug drug_general\">Tetrastarch (Hydroxyethyl starch 130/0.4; Voluven): Drug information</a></li><li><a href=\"topic.htm?path=tetrastarch-hydroxyethyl-starch-130-0-4-voluven-patient-drug-information\" class=\"drug drug_patient\">Tetrastarch (Hydroxyethyl starch 130/0.4; Voluven): Patient drug information</a></li></ul></div></div>","javascript":null}